18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence

Marafi, Fahad; Sasikumar, Arun; Fathallah, Wael; Esmail, Abdulredha

doi:10.1097/rlu.0000000000002668

Cited by 23 publications

(29 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several pilot studies with each a few patients included have demonstrated the general feasibility of non-invasive assessment of PSMA expression in glioblastoma via PET imaging (34,(40)(41)(42)(43). Whereas those case series have used either 68 Ga-labeled PSMA tracers such as 68 Ga-PSMA-11 or less common PSMA-directed tracers such as 18 F-DCFPyL or 89 Zr-Df-IAB2M, a recent case report for the first time demonstrated the feasibility of 18 F-labeled PSMA PET imaging in a glioblastoma patient (44). Several advantages of required, have started an incipient shift from 68 Ga-to 18 F-labeled PSMA-targeted tracers in PET imaging of prostate cancer as well (45).…”

Section: Discussionmentioning

confidence: 99%

PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging

et al. 2021

View full text Add to dashboard Cite

AimThe aim of the current study was to enlighten the evolution of prostate-specific membrane antigen (PSMA) expression in glioblastoma between initial diagnosis and recurrence in order to provide preliminary insight for further clinical investigations into innovative PSMA-directed treatment concepts in neuro-oncology.MethodsPatients who underwent resection for de-novo glioblastoma (GBM) and had a re-resection in case of a recurrent tumor following radiochemotherapy and subsequent chemotherapy were included (n = 16). Histological and immunohistochemical stainings were performed at initial diagnosis and at recurrence (n = 96 tissue specimens). Levels of PSMA expression both in endothelial and non-endothelial cells as well as vascular density (CD34) were quantified via immunohistochemistry and changes between initial diagnosis and recurrence were determined. Immunohistochemical findings were correlated with survival and established clinical parameters.ResultsPSMA expression was found to be present in all GBM tissue samples at initial diagnosis as well as in all but one case of recurrent tumor samples. The level of PSMA expression in glioblastoma varied inter-individually both in endothelial and non-endothelial cells. Likewise, the temporal evolution of PSMA expression highly varied in between patients. The level of vascular PSMA expression at recurrence and its change between initial diagnosis and recurrence was associated with post recurrence survival time: Patients with high vascular PSMA expression at recurrence as well as patients with increasing PSMA expression throughout the disease course survived shorter than patients with low vascular PSMA expression or decreasing vascular PSMA expression. There was no significant correlation of PSMA expression with MGMT promoter methylation status or Ki-67 labelling index.ConclusionPSMA is expressed in glioblastoma both at initial diagnosis and at recurrence. High vascular PSMA expression at recurrence seems to be a negative prognostic marker. Thus, PSMA expression in GBM might present a promising target for theranostic approaches in recurrent glioblastoma. Especially PSMA PET imaging and PSMA-directed radioligand therapy warrant further studies in brain tumor patients.

show abstract

Section: Discussionmentioning

confidence: 99%

PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging

et al. 2021

View full text Add to dashboard Cite

show abstract

“…PSMA expression was found in endothelial cells associated with neovascularization and, for these reasons, can be a very interesting marker for monitoring anti-angiogenic drugs [314] At the moment, only few studies evaluating PSMA targeted imaging of gliomas/glioblastomas in clinical practice are currently available. Moreover, most of these studies are case reports or case series [255][256][257][258][259][260][261][262][263][264]315]. Although limited, these studies confirmed that high-grade glioma/glioblastoma are PSMA-avid compared to low-grade and PSMA radioligand mainly binds vascular endothelial cells.…”

Section: Other Targets Of Tumour Microenvironmentmentioning

confidence: 84%

“…At the moment, only few studies evaluating PSMA targeted imaging of gliomas/glioblastomas in clinical practice are currently available. Moreover, most of these studies are case reports or case series [ 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 315 ]. Although limited, these studies confirmed that high-grade glioma/glioblastoma are PSMA-avid compared to low-grade and PSMA radioligand mainly binds vascular endothelial cells.…”

Section: In Vivo Imaging For the Study Of Gbm Heterogeneity And MImentioning

confidence: 99%

Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance

Valtorta

Salvatore

Rainone

et al. 2020

IJMS

View full text Add to dashboard Cite

This review highlights the importance and the complexity of tumour biology and microenvironment in the progression and therapy resistance of glioma. Specific gene mutations, the possible functions of several non-coding microRNAs and the intra-tumour and inter-tumour heterogeneity of cell types contribute to limit the efficacy of the actual therapeutic options. In this scenario, identification of molecular biomarkers of response and the use of multimodal in vivo imaging and in particular the Positron Emission Tomography (PET) based molecular approach, can help identifying glioma features and the modifications occurring during therapy at a regional level. Indeed, a better understanding of tumor heterogeneity and the development of diagnostic procedures can favor the identification of a cluster of patients for personalized medicine in order to improve the survival and their quality of life.

show abstract

“…On reviewing the titles and abstracts, 117 articles were excluded because the reported data were not within the field of interest of this review. 10 articles were selected and retrieved in full-text version [ 15 - 24 ]; no additional studies were found when screening the references of these articles. In total, 10 articles were included in the systematic review [ 15 - 24 ].…”

Section: Resultsmentioning

confidence: 99%

“…Only a few studies evaluating PSMA-targeted imaging of gliomas/glioblastomas in clinical practice are currently available. Moreover, most of these studies are case reports or case series [ 15 , 17-19, 21- 24 ] probably because few centers currently use radiolabeled PSMA PET/CT or PET/MRI, thereby reducing the population of patients analyzed globally. As a consequence, considering a very low number of reports and patients analyzed, no high quality evidence could be drawn about the role of radiolabeled PSMA in gliomas/glioblastomas; further, large prospective studies are needed to clarify the real clinical and diagnostic role of the radiolabeled PSMA in this field and its possible position in the diagnostic flow-chart.…”

Section: Discussionmentioning

confidence: 99%

Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas

Bertagna

Albano

Cerudelli

et al. 2020

CRP

View full text Add to dashboard Cite

Background: Radiolabelled prostate specific membrane antigen PSMA-based PET/CT or PET/MRI is a whole-body imaging technique currently performed for the detection of prostate cancer lesions. PSMA has been also demonstrated to be expressed by the neovasculature of many other solid tumors. Objective: The aim of this review is to evaluate the possible diagnostic role of radiolabelled PSMA PET/CT or PET/MRI in patients with gliomas and glioblastomas, by summarizing the available literature data. Methods: A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane library databases was conducted to find relevant published articles about the diagnostic performance of radiolabeled PSMA binding agents in PET/CT or PET/MRI imaging of patients with suspected gliomas or glioblastomas. Results: Seven case reports or case series and 3 studies enrolling more than 10 patients showed that gliomas and glioblastoma are PSMA-avid tumors. Conclusion: Radiolabelled PSMA imaging seems to be useful in analyzing glioma/glioblastoma. Further studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of radiolabelled PSMA in this setting and its possible position in the diagnostic flow-chart.

show abstract

18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence

Cited by 23 publications

References 9 publications

PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging

PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging

Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance

Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas

Contact Info

Product

Resources

About